Filtered By:
Management: Economics

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 383 results found since Jan 2013.

Cost-effectiveness of follow-up invasive coronary angiography after percutaneous coronary stenting: a real-world observational cohort study in Japan
Conclusions FUICA increased the costs but did not improve clinical benefits. Thus, FUICA is not economically more attractive than CF alone. Trial registration number UMIN000039768.
Source: BMJ Open - August 30, 2022 Category: General Medicine Authors: Shiina, T., Goto-Hirano, K., Takura, T., Daida, H. Tags: Open access, Health economics Source Type: research

Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France
ConclusionsHCRU and most event-related costs were lower in patients initiating apixaban compared to other OACs. Apixaban may be cost-saving compared to VKAs, and significantly cheaper than other DOACs, although cost differences are limited.
Source: The European Journal of Health Economics - August 28, 2022 Category: Health Management Source Type: research

Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis
CONCLUSION: Adherence improving interventions for NVAF patients on DOACs such as chronic disease co-management and patient education can be cost-saving and cost-effective, within a range of costs that appear reasonable to the Swedish healthcare system.PMID:35997241 | DOI:10.1080/13696998.2022.2116848
Source: Journal of Medical Economics - August 23, 2022 Category: Health Management Authors: C Blomstr öm Lundqvist S Sj älander L A Garcia Rodriguez Ö Åkerborg G Jin A Caleyachetty M Huelsebeck K Bowrin B Schaefer H Mahdessian L Hofmeister L Å Levin Source Type: research

Evaluating the cost-utility of a direct transfer to angiosuite protocol within 6  hours of symptom onset in suspected large vessel occlusion patients
CONCLUSIONS: Our economic model predicts that the implementation of a DTAS program is cost-effective compared to no organizational changes. Our model also predicts better clinical outcomes for patients in terms of functional independence and quality-adjusted life years.PMID:35960180 | DOI:10.1080/13696998.2022.2113221
Source: Journal of Medical Economics - August 12, 2022 Category: Health Management Authors: Manuel Requena Valeska Seguel Andreu Vilaseca-Jolonch Jacklyn Woods Pablo Guijarro Marc Ribo Alejandro Tomasello Carlos A Molina Source Type: research

Modeling the potential efficiency of a blood biomarker-based tool to guide pre-hospital thrombolytic therapy in stroke patients
ConclusionsThe use of a blood biomarker test to guide pre-hospital thrombolysis is cost-effective compared with standard hospital care in patients with ischemic stroke.
Source: The European Journal of Health Economics - July 27, 2022 Category: Health Management Source Type: research